{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Uveal+Melanoma", "query": { "condition": "Metastatic Uveal Melanoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 112, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Uveal+Melanoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T23:40:54.281Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02068586", "title": "Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Ciliary Body and Choroid Melanoma, Small Size", "Iris Melanoma", "Stage I Intraocular Melanoma", "Stage IIA Intraocular Melanoma", "Stage IIB Intraocular Melanoma", "Stage IIIA Intraocular Melanoma", "Stage IIIB Intraocular Melanoma", "Stage IIIC Intraocular Melanoma", "Stage I Uveal Melanoma AJCC V7", "Stage II Uveal Melanoma AJCC V7", "Stage III Uveal Melanoma AJCC V7" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Sunitinib Malate + Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2014-11-19", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-05-21T23:40:54.281Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02068586" }, { "nct_id": "NCT04552223", "title": "Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jose Lutzky, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-11-10", "completion_date": "2026-01-04", "has_results": true, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-05-21T23:40:54.281Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04552223" }, { "nct_id": "NCT04589832", "title": "Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "PAC-1", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arkadiusz Z. Dudek, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-01-11", "completion_date": "2022-06-24", "has_results": true, "last_update_posted_date": "2023-11-22", "last_synced_at": "2026-05-21T23:40:54.281Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04589832" }, { "nct_id": "NCT07136181", "title": "Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Uveal Melanoma", "Uveal Melanoma, Metastatic", "Uveal Melanoma, Recurrent", "Eye Cancer, Intraocular Melanoma", "Eye Cancer" ], "interventions": [ { "name": "NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novelwise Pharmaceutical Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2025-11-20", "completion_date": "2029-08-30", "has_results": false, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-05-21T23:40:54.281Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07136181" }, { "nct_id": "NCT01143402", "title": "Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Iris Melanoma", "Medium/Large Size Posterior Uveal Melanoma", "Ocular Melanoma With Extraocular Extension", "Recurrent Uveal Melanoma", "Small Size Posterior Uveal Melanoma", "Stage IV Uveal Melanoma" ], "interventions": [ { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2010-06", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-05-21T23:40:54.281Z", "location_count": 32, "location_summary": "Aurora, Colorado • Miami Beach, Florida • Tampa, Florida + 25 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01143402" }, { "nct_id": "NCT00003802", "title": "Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "pyrazoloacridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-02", "completion_date": "2002-10", "has_results": false, "last_update_posted_date": "2012-12-17", "last_synced_at": "2026-05-21T23:40:54.281Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003802" }, { "nct_id": "NCT01665183", "title": "Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors" ], "interventions": [ { "name": "ADI-PEG 20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Polaris Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2012-09", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-02-25", "last_synced_at": "2026-05-21T23:40:54.281Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01665183" }, { "nct_id": "NCT00096083", "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "isolated perfusion", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delcath Systems Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 56, "start_date": "2004-09", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2013-10-23", "last_synced_at": "2026-05-21T23:40:54.281Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096083" }, { "nct_id": "NCT00020475", "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extraocular Extension Melanoma", "Recurrent Intraocular Melanoma" ], "interventions": [ { "name": "gp100 antigen", "type": "DRUG" }, { "name": "interleukin-2", "type": "DRUG" }, { "name": "MART-1 antigen", "type": "DRUG" }, { "name": "Montanide ISA-51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": null, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-05-21T23:40:54.281Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020475" }, { "nct_id": "NCT00499733", "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cryoablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 19, "start_date": "2007-06", "completion_date": "2013-01-09", "has_results": false, "last_update_posted_date": "2019-01-18", "last_synced_at": "2026-05-21T23:40:54.281Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499733" } ] }